文献速递前列腺增生与排尿功能障碍

对流射频水蒸气热疗治疗良性前列腺增生的单诊室经验

Convective radiofrequency water vapor thermal therapy for benign prostatic hyperplasia: a single office experience.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2017-12-27

该回顾性研究纳入129例接受Rezūm系统对流射频水蒸气热疗的BPH患者,由单一位外科医生在诊室环境下操作。治疗后91-180天效果最明显:IPSS从基线18.3改善至6.9,Qmax从10.5提升至16.8 mL/s;90%患者停用BPH药物,86%患者愿意向朋友推荐该治疗。

要点

  • IPSS从基线18.3改善至6.9,Qmax从10.5提升至16.8 mL/s,最大效果见于91-180天。
  • 改善与起始症状评分、中叶治疗及前列腺大小无关。
  • 最常见不良事件为尿路感染(17%)和短暂性尿潴留(14%)。

核心结论

  • Rezūm射频水蒸气热疗为BPH提供微创选择,症状和尿流率有中度改善,效果似乎与前列腺大小或中叶是否存在无关,并已在单诊室环境中得到重复验证。

研究设计与样本

  • 回顾性综述,纳入129例来自单一位外科医生、接受Rezūm手术且治疗后至少4个月的患者。

主要发现

  • 最大效果见于91-180天 interval:IPSS从基线18.3改善至6.9,Qmax从10.5提升至16.8 mL/s。
  • 改善与起始症状评分、中叶治疗及前列腺大小无关。
  • 基于TRUS的前列腺体积减少17%,基于PSA的减少14%。
  • 最常见不良事件为尿路感染(17%)和短暂性尿潴留(14%)。
  • 90%患者停用BPH药物,86%患者愿意向朋友推荐该手术。

临床怎么用

  • 在诊室环境下由单一外科医生操作Rezūm水蒸气热疗,可对BPH患者症状和尿流率产生中度改善。
  • 治疗后91-180天评估显示IPSS和Qmax改善最明显,且改善似乎不受前列腺大小或中叶有无影响。
  • 治疗后多数患者(90%)可停用BPH药物,86%患者愿意推荐该手术。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Convective radiofrequency water vapor thermal therapy with the Rezūm system is a relatively new treatment for benign prostatic hyperplasia (BPH). We present results from a single surgeon in an office setting. METHODS: A retrospective review of 129 patients from a single surgeon who underwent the Rezūm procedure was performed. All patients were at least 4 months out from treatment. International prostate symptom scores (IPSS), maximum flow rates (Qmax), residual urine volumes, medication usage, and adverse events were monitored. Data were analyzed at baseline, 15-45 days, 46-90 days, and 91-180 days after treatment. A scripted patient questionnaire was attempted over the phone to all patients. It was administered by a resident and medical student who do not work in the provider's office. RESULTS: Maximal effects were noted at the 91-180 day interval. IPSS improved from a baseline of 18.3 to 6.9 and Qmax from 10.5 to 16.8 mL/s. Improvements were independent of starting symptom score, median lobe treatment, and prostate size. There was a 17% prostate volume reduction based on TRUS and 14% based on PSA. The most common adverse events were urinary tract infections (17%) and transient urinary retention (14%). In total 90% of patients were able to come off their BPH medications and 86% of patients would recommend the procedure to a friend. CONCLUSIONS: Rezūm radiofrequency water vapor thermal therapy offers a minimally invasive option for BPH management with moderate improvement in symptoms and flow rate. The results appear to be independent of prostate size or presence of a median lobe, and have now been replicated in a single office setting.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Mollengarden D, Goldberg K, Wong D, et al. Convective radiofrequency water vapor thermal therapy for benign prostatic hyperplasia: a single office experience. Prostate Cancer Prostatic Dis. 2017. PMID: 29282358. doi:10.1038/s41391-017-0022-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。